Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - ALBIREO PHARMA, INC. | albo-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - ALBIREO PHARMA, INC. | albo-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - ALBIREO PHARMA, INC. | albo-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - ALBIREO PHARMA, INC. | albo-20201231xex21d1.htm |
| EX-14.1 - EX-14.1 - ALBIREO PHARMA, INC. | albo-20201231xex14d1.htm |
| 10-K - 10-K - ALBIREO PHARMA, INC. | albo-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| 1. | Registration Statement (Form S-3 Nos. 333-238063, and 333-241680) of Albireo Pharma, Inc., and |
2.Registration Statement (Form S-8 Nos. 333-144407, 333-168903, 333-180409, 333-215264, 333-222131, 333-226718, 333-228280, and 333-233111) pertaining to equity incentive plans of Albireo Pharma, Inc;
of our reports dated February 25, 2021, with respect to the consolidated financial statements of Albireo Pharma, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2021